secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-07-29T20:05:46+00:00
Accession:  0001178913-26-003690
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion initiates Phase 2/3 trial of SIL204 in pancreatic cancer at Tel Aviv Sourasky Medical Center
--------------------------------------------------------------------------------

- First clinical site activated at Tel Aviv Sourasky Medical Center; patient screening to begin in coming weeks.
- Phase 2/3 trial of SIL204 (siRNA) for locally advanced pancreatic cancer; follows regulatory approvals from Israeli MoH and German BfArM.
- Trial includes safety run-in (~18 patients) then randomized cohort (~166 patients); dual-route administration (intratumoral + systemic).
- Additional Israeli and German sites expected to join in coming months; first patient dosing anticipated as next milestone.
- SIL204 targets broad range of KRAS mutations; KRAS mutations present in ~90% of pancreatic cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/0001178913-26-003690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/zk2635763.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-003690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer